Thermo Fisher sells its anatomic pathology business for $1.1
Industry news | 14 February, 2019 | CACLP
Recently, it was reported that Thermo Fisher Scientific had signed a definitive agreement to sell its anatomical pathology business to PHC Holdings Corporation for $1.14 billion.
Thermo Fisher’s anatomy pathology business provides microscope sections, instruments and consumables. With approximately 1,200 employees in USA, Europe and China, and annual revenues of approximately $350 million, the business is part of Thermo Fisher Scientific's professional diagnostics division.
The deal is expected to be completed in the second quarter of 2019.
Founded in 2014, PHC Holdings is a global healthcare company. Its subsidiaries include PHC Corporation and Ascensia Diabetes Care Holdings AG. The company is responsible for the development, manufacturing, sales and service of medical devices and solutions across diabetes care, diagnostics, life sciences and healthcare IT.PHC Holdings Group's consolidated net sales for the 2017 fiscal year was 192.6 billion yen, with products and services distributed in 125 countries around the world. PHC Holdings changed its name to Panasonic Healthcare Holdings Co., Ltd. in April 2018.
Press contact
Go back
